NewAmsterdam Pharma announced a positive CHMP opinion recommending marketing authorization for its cholesterol-lowering drug obicetrapib and its combination with ezetimibe, targeting patients with high LDL cholesterol. The company reported $678.3 million in cash as of June 2026 and plans to release interim PREVAIL trial results in early 2027 and topline RUBENS Phase 3 data by the end of 2026. These developments mark significant progress toward regulatory approval and potential commercialization in Europe, addressing a large unmet need in cardiovascular disease treatment. NewAmsterdam also highlighted ongoing clinical trials and upcoming investor updates to advance its pipeline.
Ethereum developers have tentatively scheduled the Glamsterdam upgrade activation on the Sepolia testnet for October 6, 2026, at 13:53 UTC. This date remains conditional as stable activation has not yet been achieved on private development networks, ...
IAMGOLD is recommended as a Buy, trading at about 8 times forward earnings with a strong balance sheet and a top-tier Canadian mine operating at full capacity. The company’s Côté and Gosselin zones now form a combined deposit exceeding 20 million oun...
Bitwise Investment Advisors announced it will terminate and liquidate its Dogecoin ETF (BWOW) with the last trading day on October 14, 2026. The decision aims to optimize Bitwise's product lineup to better meet investor needs, though minimal investor...
The PUMP token from Pump.fun fell 12.5% to $0.004002 after breaking down from a seven-day ascending channel, signaling a bearish momentum shift. Traders faced $5.42 million in liquidations, mostly long positions. The platform added 20 new token pairs...
Bitcoin dropped to $76,651 following the release of US Producer Price Index data showing a 5.4% annual increase, driven by rising energy costs. This led to $562 million in crypto liquidations within 24 hours, mostly affecting long positions worth $48...
